Bridges Investment Management Has Boosted Gilead Sciences (GILD) Holding; Shorts at Myos Rens Tech (MYOS) Lowered By 8.11%

Bridges Investment Management Inc increased Gilead Sciences Inc (GILD) stake by 34.9% reported in 2017Q3 SEC filing. Bridges Investment Management Inc acquired 20,445 shares as Gilead Sciences Inc (GILD)’s stock declined 8.05%. The Bridges Investment Management Inc holds 79,020 shares with $6.40M value, up from 58,575 last quarter. Gilead Sciences Inc now has $97.53B valuation. The stock increased 0.76% or $0.56 during the last trading session, reaching $74.66. About 6.64M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since January 4, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Myos Rens Tech Incorporated (NASDAQ:MYOS) had a decrease of 8.11% in short interest. MYOS’s SI was 531,700 shares in January as released by FINRA. Its down 8.11% from 578,600 shares previously. With 101,800 avg volume, 5 days are for Myos Rens Tech Incorporated (NASDAQ:MYOS)’s short sellers to cover MYOS’s short positions. The SI to Myos Rens Tech Incorporated’s float is 15%. The stock increased 4.96% or $0.07 during the last trading session, reaching $1.48. About 422,795 shares traded or 12.38% up from the average. MYOS RENS Technology Inc. (NASDAQ:MYOS) has risen 31.03% since January 4, 2017 and is uptrending. It has outperformed by 14.33% the S&P500.

MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company has market cap of $9.39 million. The firm primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. It currently has negative earnings. The Company’s products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes.

Since August 1, 2017, it had 0 buys, and 9 sales for $36.34 million activity. $6.09 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by MARTIN JOHN C. The insider Alton Gregg H sold $2.08M. Meyers James R had sold 60,000 shares worth $4.99 million. Washington Robin L also sold $4.40M worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares.

Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.10, from 0.93 in 2017Q2. It improved, as 96 investors sold GILD shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Cornerstone Advsr has 0.29% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 5,164 shares. The California-based Bennicas Associate has invested 1.56% in Gilead Sciences, Inc. (NASDAQ:GILD). Stephens Ar holds 69,768 shares. Greatmark Inv Prtn, Georgia-based fund reported 75,295 shares. Violich Cap Mngmt Inc reported 1.92% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). The Pennsylvania-based Hudock Cap Group Lc has invested 0.01% in Gilead Sciences, Inc. (NASDAQ:GILD). American Beacon Advisors invested in 1,293 shares. Leuthold Gru Ltd Liability Company holds 0.59% or 71,887 shares. Somerville Kurt F reported 30,117 shares. North Carolina-based Piedmont Invest Advsrs Lc has invested 0.62% in Gilead Sciences, Inc. (NASDAQ:GILD). Wetherby Asset owns 42,829 shares. Dana Investment Advsrs holds 28,279 shares or 0.11% of its portfolio. Monetary Group Incorporated owns 26,995 shares. Winfield accumulated 320 shares. Perella Weinberg Prns Capital Limited Partnership holds 6,928 shares.